Drugs / Moxonidine

Trials 15 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 02 trials
Phase 0 NCT04140721 Aug 2021 → Dec 2025 overdue postural orthostatic tachycardia syndrome Vanderbilt University Medical Center Active not recruiting No outcome recorded
Phase 0 NCT04050410 Aug 2019 → Dec 2025 overdue postural orthostatic tachycardia syndrome Vanderbilt University Medical Center Active not recruiting No outcome recorded
Phase 11 trial
Phase 1 NCT04329806 Feb 2021 → Jul 2022 abdominal obesity-metabolic syndrome Italo Biaggioni Terminated No outcome recorded
Phase 1/21 trial
Phase 1/2 NCT05312892 May 2022 → Dec 2028 expected hypertensive disorder, obesity disorder Vanderbilt University Medical Center Recruiting No outcome recorded
Phase 31 trial
Phase 3 NCT00160277 Jul 2005 → ? essential hypertension Solvay Pharmaceuticals Completed No outcome recorded
Phase 48 trials
Phase 4 NCT04023565 Mar 2019 → Jun 2020 hypertensive disorder, metabolic syndrome X Sergey V. Nedogoda Unknown No outcome recorded
Phase 4 NCT04479813 Jul 2015 → Mar 2022 sympathetic nervous system disorder Royal Perth Hospital Completed No outcome recorded
Phase 4 NCT04474899 Jun 2015 → Feb 2024 hypertensive disorder, obesity disorder Royal Perth Hospital Unknown No outcome recorded
Phase 4 NCT01567124 May 2012 → ? schizophrenia Baker Heart and Diabetes Institute Withdrawn No outcome recorded
Phase 4 NCT01360710 Jan 2012 → Jan 2014 abdominal obesity-metabolic syndrome, hypertensive disorder Baker Heart and Diabetes Institute Unknown No outcome recorded
Phase 4 NCT01094769 Apr 2011 → Jan 2020 diabetic kidney disease Baker Heart and Diabetes Institute Completed No outcome recorded
Phase 4 NCT01138423 Aug 2010 → Feb 2012 hypertensive disorder, metabolic syndrome X UMC Utrecht Completed No outcome recorded
Phase 4 NCT05147753 Jan 2010 → Jun 2014 hypertensive disorder, obesity disorder Aristotle University Of Thessaloniki Completed No outcome recorded
Phase not applicable2 trials
NCT02355821 Apr 2015 → Jun 2018 hypertensive disorder, osteoporosis National Research Center for Preventive Medicine Completed No outcome recorded
NCT00518479 Sep 2003 → Apr 2004 hypertensive disorder, hypertensive heart disease University of Leeds Completed No outcome recorded
Also used as a comparator or background therapy in 4 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 31 trial
Phase 3 NCT00244504 Comparator Nov 2002 → Mar 2006 heart disorder University Hospital, Basel, Switzerland Terminated No outcome recorded
Phase 43 trials
Phase 4 NCT01791699 Comparator Aug 2012 → Nov 2013 atrial fibrillation Spyridon Deftereos Completed No outcome recorded
Phase 4 NCT01504321 Comparator May 2012 → May 2015 polycystic ovary syndrome Baker Heart and Diabetes Institute Completed No outcome recorded
Phase 4 NCT01180231 Comparator Sep 2010 → Sep 2014 obesity disorder Baker Heart and Diabetes Institute Unknown No outcome recorded

Evidence & citations 16 cited values

Every value below carries the sentence it was read from. 21 sources stand behind the page.

FieldValueCited text
Known as Moxonidine ClinicalTrials.gov intervention name — accepted as the source's own label NCT02355821
18

NCT04050410

NCT01138423

NCT01791699

NCT04140721

NCT00244504

NCT01504321

NCT00518479

NCT01567124

NCT04329806

NCT00160277

NCT01360710

NCT01094769

NCT05147753

NCT01180231

NCT05312892

NCT04479813

NCT04474899

NCT04023565

Known as BDF-5896 ChEMBL registry synonym — accepted as the source's own label CHEMBL19236
Known as BE-5895 ChEMBL registry synonym — accepted as the source's own label CHEMBL19236
Known as Brand name = Physiotens Brand name = PhysiotensNCT01360710
Known as Cynt ChEMBL registry synonym — accepted as the source's own label CHEMBL19236
Known as Fisiotens ChEMBL registry synonym — accepted as the source's own label CHEMBL19236
Known as LY-326869 ChEMBL registry synonym — accepted as the source's own label CHEMBL19236
Known as Moxonidina ChEMBL registry synonym — accepted as the source's own label CHEMBL19236
Known as MOXONIDINE HYDROCHLORIDE ChEMBL registry synonym — accepted as the source's own label CHEMBL19236
Known as Normatens ChEMBL registry synonym — accepted as the source's own label CHEMBL19236
Known as Physiotens ChEMBL registry synonym — accepted as the source's own label CHEMBL19236
Action Activate “Nischarin agonist” CHEMBL19236
Action Inhibit “the moxonidine molecule is known to reduce the AE protein activity.” NCT02355821
Modality Small molecule CHEMBL19236
Route Oral “Small oral doses of moxonidine did not reduce the incidence of perioperative myocardial ischaemia” PMID 17968979 Dec 2007
Target NISCH Nischarin agonist” CHEMBL19236